Clinical Trials - APLS

NCT IDTitleStatusPhasesStart DateCompletion DatePrimary Completion Date
NCT07213960A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental GlomerulosclerosisNOT_YET_RECRUITINGPHASE2, PHASE32025-122029-122029-10
NCT07214740Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled SyringeNOT_YET_RECRUITINGPHASE32025-102026-012026-01
NCT07020832A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft TransplantationNOT_YET_RECRUITINGPHASE32025-092028-082027-08
NCT05809531An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative GlomerulonephritisACTIVE_NOT_RECRUITINGPHASE32023-05-292027-072027-07
NCT05067127Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative GlomerulonephritisCOMPLETEDPHASE32021-11-122025-01-142024-06-26
NCT04572854Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGNACTIVE_NOT_RECRUITINGPHASE22021-09-072026-012023-02-27
NCT04770545An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMDACTIVE_NOT_RECRUITINGPHASE32021-03-042026-092025-09
NCT04901936A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)RECRUITINGPHASE22021-02-042028-122028-12
NCT04579666MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)TERMINATEDPHASE22020-09-302023-07-132023-03-31
NCT04402060A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19COMPLETEDPHASE1, PHASE22020-05-282021-02-132021-02-13
NCT04085601A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNHCOMPLETEDPHASE32019-08-272021-06-232021-06-23
NCT03777332Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic AtrophyCOMPLETEDPHASE12018-11-052021-04-012021-04-01
NCT03525613A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular DegenerationCOMPLETEDPHASE32018-08-312022-06-282021-06-28
NCT03525600Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular DegenerationCOMPLETEDPHASE32018-08-312022-06-202021-06-21
NCT03531255Pegcetacoplan Long Term Safety and Efficacy Extension StudyACTIVE_NOT_RECRUITINGPHASE32018-08-272025-062025-06
NCT03593200A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNHCOMPLETEDPHASE22018-08-162019-10-222019-10-22
NCT03500549Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)COMPLETEDPHASE32018-06-142020-08-132019-11-14
NCT03453619Phase II Study Assessing Safety and Efficacy of APL-2 in GlomerulopathiesCOMPLETEDPHASE22018-02-262023-08-262020-04-16
NCT03465709Pegcetacoplan (APL-2) in Neovascular AMDTERMINATEDPHASE1, PHASE22018-02-142019-04-052019-04-05
NCT03226678Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)COMPLETEDPHASE22017-08-312022-09-122022-09-12
NCT02588833Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects.COMPLETEDPHASE12015-12-012019-08-262019-08-26
NCT02503332Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic AtrophyCOMPLETEDPHASE22015-09-242018-01-172017-07-14
NCT02264639A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNHCOMPLETEDPHASE12015-02-232018-10-222018-10-22
NCT02461771Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMDCOMPLETEDPHASE12015-01-282016-03-082016-03-08